Stroke patients have cholesterol level's greater than recommended by NCEP-ATP III guidelines

被引：0
|
作者：
不详
机构：
来源：
FUTURE LIPIDOLOGY | 2007年 / 2卷 / 02期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：124 / 124
页数：1
相关论文
共 27 条
  • [1] The prevalence of dyslipidemia by new guidelines NCEP-ATP III in Korean type 2 diabetic patients
    Kim, DK
    Park, MK
    Kang, DY
    Lee, HJ
    DIABETES, 2002, 51 : A495 - A495
  • [2] Testing national cholesterol education program-adult treatment panel III (NCEP-ATP III) guidelines for central obesity in African Americans
    Sen, Salbyasachi
    Chow, Carson C.
    Ricks, Madia
    Sebring, Nancy G.
    Frempong, Barbara A.
    Sumner, Anne E.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (06) : E113 - E114
  • [3] Achievement in SingApore of cholesterol targets (A- SACT): Implications of the July 2004 NCEP-ATP III recommendations
    Ho, KT
    Chin, KW
    Ng, KS
    Deb, B
    Alemao, E
    Rajagopalan, S
    Yin, DD
    CIRCULATION, 2005, 111 (20) : E354 - E354
  • [4] Are the patients with metabolic syndrome as defined by International Diabetes Federation criteria more insulin resistant than NCEP-ATP III criteria?
    Kim, J. -H.
    Kwon, H. -S.
    Park, Y. -M.
    Lim, S. -Y.
    Cho, J. -H.
    Kim, S. -R.
    Chang, S. -A.
    Song, K. -H.
    Yoon, K. -H.
    Lee, W. C.
    Cha, B. -Y.
    Lee, K. -W.
    Kang, S. -K.
    Son, H. -Y
    DIABETOLOGIA, 2006, 49 : 236 - 237
  • [5] Evaluation of the hypercholesterolemia care cascade and compliance with NCEP-ATP III guidelines in Iran based on the WHO STEPS survey
    Djalalinia, Shirin
    Khosravi, Sepehr
    Yoosefi, Moein
    Salahi, Sarvenaz
    Varniab, Zahra Shokri
    Golestani, Ali
    Rezaei, Nazila
    Kazemi, Ameneh
    Dilmaghani-Marand, Arezou
    Rezaei, Negar
    Ghasemi, Erfan
    Ahmadi, Naser
    Rashidi, Mohammad-Mahdi
    Farzi, Yosef
    Rezaee, Kamyar
    Nasserinejad, Maryam
    Azadnajafabad, Sina
    Abdolhamidi, Elham
    Haghshenas, Rosa
    Derouei, Arefeh Alipour
    Rankohi, Azadeh Momen Nia
    Farzadfar, Farshad
    LIPIDS IN HEALTH AND DISEASE, 2025, 24 (01)
  • [6] The NCEP-ATP III recommendations result in undertreatment of the lipid abnormalities of patients with impaired fasting glucose
    Aguilar-Salinas, CA
    Rojas, R
    Gomez-Perez, FJ
    Franco, A
    Riostorres, JM
    Valles, V
    Olaiz, G
    Rull, JA
    DIABETES, 2002, 51 : A150 - A150
  • [7] Frequency of Metabolic Syndrome among Hemodialysis Patients According to NCEP-ATP III and IDF Definitions
    Ucar, Edip
    Huzmeli, Can
    Guven, Oguz
    Savas, Nazan
    Gullu, Murat
    Asilyoruk, Sema
    Kuvandik, Ceren
    Temizkan, Aysegul
    Kuvandik, Guven
    RENAL FAILURE, 2009, 31 (03) : 221 - 228
  • [8] NCEP-ATP III guidelines may underestimate the need for statin therapy in at-risk individuals: A cross-sectional 64-slice MDCT study
    Garg, Pankai
    Zynda, Todd
    Mosiuc, Florin
    Khattar, Ramni
    Malik, Shaista
    Saremi, Farhood
    Narula, Jagat
    Gurudevan, Swaminatha
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : A144 - A145
  • [9] Are the patients with metabolic syndrome as defined by NCEP-ATP III criteria truely insulin resistant? from Chungjoo Insulin Resistance syndrome Cohort (CIRC) Study
    Kwon, HS
    Park, YM
    Lim, DJ
    Ko, SH
    Lee, JM
    Kim, SR
    Ahn, YB
    Yoo, SJ
    Song, KH
    Yoon, KH
    Lee, WC
    Cha, BY
    Lee, KW
    Kang, SK
    Son, HY
    DIABETOLOGIA, 2005, 48 : A222 - A222
  • [10] Hemodialysis patients receiving a greater Kt dose than recommended have reduced mortality and hospitalization risk
    Maduell, Francisco
    Ramos, Rosa
    Varas, Javier
    Martin-Malo, Alejandro
    Molina, Manuel
    Perez-Garcia, Rafael
    Marcelli, Daniele
    Moreso, Francesc
    Aljama, Pedro
    Ignacio Merello, Jose
    KIDNEY INTERNATIONAL, 2016, 90 (06) : 1332 - 1341
123